Slide 1: Analyst and Investor Call to Discuss the First COVID-19 Comprehensive Approach
Analyst and Investor Call to Discuss the First COVID-19 Comprehensive Approach: Pfizer-BioNTech Vaccine and Pfizer’s Novel Oral Antiviral Treatment Candidate December 17, 2021 Breakthroughs that change patients’ lives
Slide 2: Christopher Stevo
Christopher Stevo Senior Vice President, Chief Investor Relations Officer Breakthroughs that change patients’ lives
Slide 3: Forward-Looking Statements and Other Notices
Forward-Looking Statements and Other Notices This presentation and our discussions during this conference call include forward-looking statements about, among other topics, our efforts to combat COVID-19; the BNT162b2 mRNA vaccine program and the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) (includin
Slide 4: Speakers
Speakers Mikael Dolsten, M.D., Ph.D. Nanette Cocero, Ph.D. Kathrin Jansen, Ph.D. Luis Jodar, Ph.D. William Gruber, M.D. Chief Scientific Officer and President, Global President, Senior Vice President & Senior Vice President & Senior Vice President, Worldwide Research Development Vaccines Head of Vac
Slide 5: Mikael Dolsten, M.D., Ph.D.
Mikael Dolsten, M.D., Ph.D. Chief Scientific Officer and President, Worldwide Research Development and Medical, Pfizer Breakthroughs that change patients’ lives
Slide 6: Tools to Fight the Pandemic Exist, But Unmet Needs Remain
Tools to Fight the Pandemic Exist, But Unmet Needs Remain SCIENTIFIC Unmet Needs SOCIETAL Unmet Needs Variants of concerns (e.g., Omicron) Vaccine hesitancy remains Waning immunity and boosters Vaccines in younger people Highly active oral therapies Equitable access to medical advances Pandemic to e
Slide 7: Scientific Approach to Surveillance and Variants of Concern
Scientific Approach to Surveillance and Variants of Concern 1 2 3 4 Conduct Test Understand Boosting Immunity Surveillance & Vaccine & Therapeutic Real World by Existing or Variant Predictive Modeling Effectiveness Evidence Targeted Vaccines Monitor the real-world effectiveness Engineered (pseudo)vi
Slide 8: Approach to Reduce Viral Spread, Prevent Hospitalizations and Save Lives
Approach to Reduce Viral Spread, Prevent Hospitalizations and Save Lives PAXLOVID for PREVENTION for TREATMENT* Potential treatment option for Providing strong protection patients who become infected • EUA for those aged 5 though 15; • In Phase 2/3 study, strong efficacy in full approval for 16+ yea
Slide 9: Scaling Vaccine Production to Fight Against COVID-19
Scaling Vaccine Production to Fight Against COVID-19 Manufactured more than 3B doses in 2021; 4B projected for 2022 Key Enablers 4B DOSES • Reduced manufacturing time ≈ 110 days average of 60 days 3B DOSES • Increased the number of sites from 6 30 ‒ >75% of the total volume occurring within the
Slide 10: Launching a Potential Oral Anti-Viral to Continue the Fight Against COVID-19
Launching a Potential Oral Anti-Viral to Continue the Fight Against COVID-19 Projected to Manufacture 80M Treatment Courses in 2022 2022 Projections 80M Treatment Courses 50M Treatment Courses 20M Treatment 10M Courses Treatment Courses MAY 2021 AUG 2021 SEPT 2021 NOV 2021 Plan Plan Plan Plan 10
Slide 11: Lightspeed Paradigm for Vaccine and Treatment Development
Lightspeed Paradigm for Vaccine and Treatment Development Parallel Expert Dose Streamlined At-Risk Faster Regulatory Testing Selection Governance Investment Dialogue Design and test Optimization of Empowered Teams and Swift Large Commercial Simplified, multiple constructs dose for vaccines Decision-
Slide 12: Kathrin Jansen, Ph.D.
Kathrin Jansen, Ph.D. Senior Vice President & Head of Vaccine R&D Breakthroughs that change patients’ lives
Slide 13: Our Continued Commitment to Help Transform the COVID-19 Pandemic Into a Manageable Endemic
Our Continued Commitment to Help Transform the COVID-19 Pandemic Into a Manageable Endemic 13
Slide 14: COMIRNATY: Only Vaccine Against COVID-19 Authorized in Individuals 5 Years and Older
COMIRNATY: Only Vaccine Against COVID-19 That is Authorized in Individuals 5 Years of Age and Older Data from Ph2/3: BNT162b2 Vaccine Efficacy Post Dose 2 Age Efficacy (%) Authorization/Approval 5 through 11 90.71 EUA – October 2021 12 through 15 100.02 EUA – May 2021 95.03 EUA – December 2020 16 an
Slide 15: Evidence of Declining BNT162b2 Efficacy Over Time
Evidence of Declining BNT162b2 Efficacy Against COVID-19 Over Time Yet Vaccine Remains Highly Effective Against Severe COVID-19 Disease, Hospitalization and Death BNT162b2 Phase 3 Efficacy Decreases Slowly Over Time – Randomized Control Trial 100 96.2% Vaccine Efficacy 80 90.1% 83.7% 60 40 20 0 >7 d
Slide 16: 3rd BNT162b2 Dose Substantially Increases Neutralization Titers and Breadth
3rd BNT162b2 Dose Substantially Increases Neutralization Titers and Breadth against SARS-CoV-2 VOCs Compared to 2 Doses of BNT162b2 65-85 y/o n=12/group 104 2032 1567 50% Serum Neutralizing Titer 261 PRNTWT 103 PRNTBeta 76 41 102 20 Lower Limit 10 10 of Detection 101 Pre-Dose 1 1 Month PD2 8 Months
Slide 17: 3rd BNT162b2 Dose Increases Titers and Reduces Gap Against Delta
3rd BNT162b2 Dose Substantially Increases Titers Over 2 Doses and Reduces Gap Between Wild-Type and Delta Neutralization 18-55 Years Old 65-85 Years Old n=11/group n=12/group 1613 1479 50% Serum Neutralizing Titer 104 10000 1546 1321 103 1000 310 241 196 123 1002 10 Lower Limit of Detection 101 10 1
Slide 18: 3rd Dose Restores High Vaccine Efficacy and Effectiveness Against Delta
3rd BNT162b2 Dose Restores High Levels of Vaccine Efficacy and Demonstrates High Effectiveness Against Delta Phase 3 booster dose highly effective against symptomatic COVID-191 BNT162b2 (N=4695) Placebo2 (N=4671) 3 Confirmed COVID-19 Confirmed COVID-19 Relative Vaccine Efficacy % (95% CI) 3 Placebo
Slide 19: BNT162b2-elicited Sera Effectively Neutralize SARS-CoV-2 Spike Variants
BNT162b2-elicited Sera Effectively Neutralize SARS-CoV-2 Spike Variants Viruses are isogenic, recombinant SARS-CoV-2 strains, with variant spike coding sequences on a common, USA-WA1/2020 genetic background 194 288 ? Lower Limit of Detection Mu Omicron Circles: 2 weeks PD2. Triangles: 4 weeks PD2 Da
Slide 20: Omicron Variant Contains Larger Number of Mutations Than Other Variants of Concern
Omicron Variant Contains Larger Number of Mutations Than Other Variants of Concern (VOC) NTD RBD 685 816 Alpha B.1.1.7 1 1273 NTD RBD 685 816 1 1273 Beta B.1.351 NTD RBD 685 816 1 1273 Gamma P.1 NTD RBD 685 816 1 1271 Delta B.1.617.2 NTD RBD 685 816 1 1270 Omicron B.1.1.529 Δ211 S371L Q493R L212I S3
Slide 21: Post Dose Omicron Neutralization Titers
Post Dose 3 Omicron Neutralization Titers are Similar to Those Observed After Two Doses for Wild-Type Which Have Been Associated with High Effectiveness 155 6 36 398 154 191 339 Wild-Type Omicron Variant Beta Variant Neutralization Titers Delta Variant (Pseudo Virus*) Limit of Detection 21 Days Afte
Slide 22: Establishing Regulatory Pathway for 100-Day Potential Vaccine Update
Establishing Regulatory Pathway for 100-Day Potential Vaccine Update Study Design • mRNA allows for 100- day pivot to updated Previously Analysis vaccine, if needed, and 3 Establish is subject to regulatory experienced BNT162b2 – BNT162b2 Noninferiority of 1- 3 Weeks VOC month PD3 VOC Neutralization
Slide 23: Careful Dose Ranging Study to Balance Immunogenicity with Tolerability
Careful Dose Ranging Study to Balance Immunogenicity with Acceptable Tolerability Profile 6 mo to <2 Years* 2 to <5 Years 2 to <5 Years 5-11 Years 16-25 Years N=16 N=16 N=32 N=1511 N=531 100 Dose 1 80 60 40 Chills Fever % of Participants 20 Fever Chills Chills Chills Fever Fever Fever 0 3 ug Fever 3
Slide 24: Careful Dose Ranging Study: Neutralizing Titers
Careful Dose Ranging Study to Balance Immunogenicity with Acceptable Tolerability Profile 2 to <5 y/o 3 µg 10 µg N=9 N=14 N=31 N=15 N=16 N=30 N=30 50% virus neutralizing titer Geometric Mean Titer Limit of Detection 6months - <12 data from Phase 1 NCT04816643; 12-15 and 16-25 data from Phase 3 NCT04
Slide 25: Pediatric Program Update
Pediatric Program Update 25
Slide 26: Looking Ahead: 2022 and Beyond
Looking Ahead: 2022 and Beyond We Are Prepared For Each Scenario Pandemic Scenarios Virus is leaving COVID-19 Cases Gain approval for all populations and age groups Virus is staying Monitor variant epidemiology COVID-19 Cases Regulatory pathway to update vaccine, if necessary Virus is changing COVID
Slide 27: Nanette Cocero, Ph.D.
Nanette Cocero, Ph.D. Global President, Vaccines Breakthroughs that change patients’ lives
Slide 28: Pfizer is the Global Leader in Vaccines for the Prevention of COVID-19
Pfizer is the Global Leader in Vaccines for the Prevention of COVID-19 Lightspeed to Market Doses Shipped Globally Total Doses Manufactured 1st >2.4B ~3B Authorizations/Approvals Across broad populations To over 160 countries Calendar Year 2021 16+ BLA Value to Investors 16+ EUA 12-15yrs. EUA (Aug 2
Slide 29: US and EU Vaccine Doses Administered and Projected Deliveries
“ 1 ” US Vaccine Doses Administered by Manufacturer2 Comirnaty 2021 (Calendar Year) Projected Doses Delivered (millions)4 Cumulative Doses (Millions) 500 US 400 365 300 Pfizer/BNT 58% 200 L&MIC Moderna 38% 100 1,100 0 J&J 4% 12-Jan-21 01-Apr-21 04-Jun-21 24-Jul-21 26-Oct-21 29-Nov-21 EU 660 EU Vacci
Slide 30: Comirnaty: A Large, Long-Term Sustainable Business for Pfizer
Comirnaty: A Large, Long-Term Sustainable Business for Pfizer In Pandemic or Endemic market, Pfizer is well positioned to continue to be a clear market leader 2022 2023 2024 and Beyond Pandemic Hybrid Endemic PFE Contracts* $31B revenue/1.9B doses >500m doses to date N/A Pfizer Expectations Signific
Slide 31: Demonstrated Success in Manufacturing Innovation, Scale, and Agility
Demonstrated Success in Manufacturing Innovation, Scale, and Agility Enables Significant and Sustained Advantage Expanded Reduced Improved Innovation in Poised to Manufacturing Production Product Logistics and Address Potential Footprint Time Formulation Shipping Vaccine-Escape Variants • Ability to
Slide 32: Pfizer's Differentiated End-to-End Capabilities Positions Us to Lead
Pfizer’s Differentiated End-to-End Capabilities Positions Us to Lead in the Marketplace as the Virus Evolves Commercial Product and Scientific Leadership Manufacturing Leadership Expertise Global Footprint, Contracting Capabilities, Agility, Product Innovation, Clinical Epidemiological Experience, E
Slide 33: PAXLOVID (nirmatrelvir; ritonavir) – COVID-19 Antiviral Candidate
PAXLOVID™ (nirmatrelvir; ritonavir) – COVID-19 Antiviral Candidate Breakthroughs that change patients’ lives
Slide 34: Angela Lukin
Angela Lukin Global President, Hospital Breakthroughs that change patients’ lives
Slide 35: Building Upon a Strong Heritage in Pfizer Hospital
With the Protease Inhibitor Candidate, We Are Building Upon a Strong Heritage in Pfizer Hospital A Complex and Broad Portfolio Supply Reliability Manufacturing Expertise of Critical Medicines 300+ >95% 98.6% 44 14+ Medicines across Of our Sterile Injectable products are Medically necessary1 Medicine
Slide 36: Annaliesa Anderson, Ph.D., FAAM
Annaliesa Anderson, Ph.D., FAAM Chief Scientific Officer, Bacterial Vaccines and Hospital Breakthroughs that change patients’ lives
Slide 37: PAXLOVID: First in Class Oral Protease Inhibitor in Three Target Populations
PAXLOVID (nirmatrelvir; ritonavir): A First in Class COVID-19 Oral Protease Inhibitor Candidate is Being Developed in Three Target Patient Populations* Patients at “HIGH RISK” of Patients at “STANDARD RISK” of progressing to severe COVID-19, Post Exposure Prophylaxis progressing to severe illness in
Slide 38: Unprecedented Urgency to Deliver an Oral Therapeutic for COVID-19
Unprecedented Urgency to Deliver an Oral Therapeutic Designed For The Treatment of COVID-19 1st commercial Phase 3 Phase 3 Phase 3 batches EPIC-SR Interim Program Toxicology EPIC-HR EPIC-SR EPIC-PEP manufactured Analysis Initiated Study Start Start Start Start 344 Kg Readout Design Phase 03/20 07/20
Slide 39: PAXLOVID: An Oral Antiviral Candidate for the Treatment of COVID-19
PAXLOVID: An Oral Antiviral Candidate for the Treatment of COVID-19 PAXLOVID Treatment: Nirmatrelvir (300 mg) with Ritonavir (100 mg) PO BID Mechanism of Action (MOA) Nirmatrelvir (PF-7321332): Inhibition of the SARS-CoV-2 main protease (Mpro) prevents viral replication through blocking the protease
Slide 40: Non-clinical Supportive Data for Nirmatrelvir
Non-clinical Supportive Data for Potential First In Class SARS-CoV-2-Mpro: Nirmatrelvir Nirmatrelvir demonstrated compelling antiviral Nirmatrelvir is a potent inhibitor activity across variants of concern/interest of the Omicron Mpro Antiviral activity in Variant (first identified) vero cells* – EC
Slide 41: Phase 1 Data Confirmed Potential of PAXLOVID as Broad Coronavirus Antiviral
Phase 1 Data Confirmed the Potential of PAXLOVID as a Broad Coronavirus Antiviral Therapeutic PAXLOVID (300 mg nirmatrelvir + 100 mg ritonavir), twice a day Viral EC90^ ^ EC90, concentration of nirmatrelvir that is 90% of the maximal effective concentration; MERS: Vero81 cells +1 uM P-gp inhibitor;
Slide 42: James Rusnak, M.D., Ph.D.
James Rusnak, M.D., Ph.D. Chief Development Officer, Internal Medicine and Hospital Breakthroughs that change patients’ lives
Slide 43: PAXLOVID Phase 3 Clinical Development Program
PAXLOVID Phase 3 Clinical Development Program High Risk Standard Risk Household Contact Pivotal Study EPIC-HR EPIC-SR EPIC-PEP Recruitment Target 3,0001 1,140 2,660 No risk factors for severe Household contacts of At least one risk factor for Population COVID-19 infection; or with individuals infect
Slide 44: PAXLOVID Phase 3 Clinical Development Program
PAXLOVID Phase 3 Clinical Development Program High Risk Standard Risk Household Contact Pivotal Study EPIC-HR EPIC-SR EPIC-PEP Recruitment Target 3,0001 1,140 2,660 No risk factors for severe Household contacts of At least one risk factor for Population COVID-19 infection; or with individuals infect
Slide 45: EPIC-HR: Study Design and Key Demographics
Evaluation of Protease Inhibition for COVID-19 – High-Risk (EPIC-HR): Study Design and Key Demographics Design / Key Entry Criteria Examples of High-Risk Conditions • Randomized, blinded, placebo-controlled • BMI >25 • Cardiovascular disease • Unvaccinated patients ≥18 years of age, ≥1 condition • D
Slide 46: EPIC-HR: Key Endpoints
EPIC-HR: Key Endpoints EPIC-HR • Proportion of participants with COVID-19 related Primary Endpoint hospitalization or death from any cause through Day 28 in the mITT cohort (≤3 days since symptom onset) • Proportion of participants with COVID-19 related hospitalization or death from any cause throug
Slide 47: EPIC-HR Primary Endpoint: Hospitalization and Death through Day 28 mITT Population
EPIC-HR Primary Endpoint: Hospitalization and Death through Day 28 mITT Population (≤3 days since symptom onset) Full Analysis 45% Interim Analysis Results Results PAX PBO RRR PAX PBO RRR Hospitalization or 3 / 389 27 / 385 89% death by Day 28 (0.8%) (7.0%) p<0.0001 7 Death by Day 28 0 (1.8%) Abbrev
Slide 48: EPIC-HR Primary Endpoint: Hospitalization and Death through Day 28 mITT Population
EPIC-HR Primary Endpoint: Hospitalization and Death through Day 28 mITT Population (≤3 days since symptom onset) Full Analysis 45% Interim Analysis Results Results PAX PBO RRR PAX PBO RRR Hospitalization or 3 / 389 27 / 385 89% 5 / 697 44 / 682 89% death by Day 28 (0.8%) (7.0%) p<0.0001 (0.7%) (6.4%
Slide 49: EPIC-HR: Hospitalization and Death through Day 28 mITT1 Population
EPIC-HR: Hospitalization and Death through Day 28 mITT1 Population (≤5 days since symptom onset) Full Analysis 45% Interim Analysis Results Results PAX PBO RRR PAX PBO RRR Hospitalization or 6 / 607 41 / 612 85% death by Day 28 (1.0%) (6.7%) p<0.0001 10 Death by Day 28 0 (1.6%) Abbreviations: PAX =
Slide 50: EPIC-HR: Hospitalization and Death through Day 28 mITT1 Population
EPIC-HR: Hospitalization and Death through Day 28 mITT1 Population (≤5 days since symptom onset) Full Analysis 45% Interim Analysis Results Results PAX PBO RRR PAX PBO RRR Hospitalization or 6 / 607 41 / 612 85% 8 / 1039 66 / 1046 88% death by Day 28 (1.0%) (6.7%) p<0.0001 (0.8%) (6.3%) p<0.0001 10
Slide 51: EPIC-HR: Approximate 10-fold Reduction in Viral Load at Day 5
EPIC-HR: Approximate 10-fold Reduction in Viral Load at Day 5 EPIC-HR PAX PBO N 211 240 Least Squares Mean Change from Baseline -2.69 -1.75 Least Squares Mean Difference -0.93 1-sided 80% CI (-∞, -0.83) Dataset: MITT1 (≤5 days since symptom onset) ~10-fold decrease (1 Log10) in viral load, relative
Slide 52: EPIC-HR: Final Analysis – Safety Outcomes
EPIC-HR: Final Analysis – Safety Outcomes Safety Outcome Results PAX PBO Treatment-emergent adverse events 23% 24% (Most mild in intensity) Serious adverse events 1.6% 6.6% Adverse events leading to 2.1% 4.2% discontinuation of treatment Abbreviations: PAX = PAXLOVID; PBO = placebo Pfizer Announces
Slide 53: PAXLOVID Phase 3 Clinical Development Program
PAXLOVID Phase 3 Clinical Development Program High Risk Standard Risk Household Contact Pivotal Study EPIC-HR EPIC-SR EPIC-PEP Recruitment Target 3,0001 1,140 2,660 No risk factors for severe Household contacts of At least one risk factor for Population COVID-19 infection; or with individuals infect
Slide 54: EPIC-SR: Study Design and Key Demographics
Evaluation of Protease Inhibition for COVID-19 - Standard Risk (EPIC-SR): Study Design and Key Demographics Design / Key Entry Criteria Key Demographics • Randomized, blinded, placebo-controlled • Average age – early 40’s • Unvaccinated patients ≥18 years of age, without conditions indicative for •
Slide 55: EPIC-SR: Key Endpoints
EPIC-SR: Key Endpoints EPIC-SR • Time (days) to sustained alleviation of all targeted COVID-19 Primary Endpoint sign / symptoms through Day 28 in the mITT cohort (≤3 days since symptom onset) • Time (days) to sustained alleviation of all targeted COVID-19 sign / symptoms through Day 28 in the mITT1
Slide 56: EPIC-SR: Primary Endpoint Definition
EPIC-SR: Primary Endpoint Definition Definition of Time to Sustained Alleviation Signs and Symptoms Attributable to COVID-19 First of 4 Consecutive Daily Signs and Symptoms collection Baseline Severity Day Severity • Cough Absent Absent • Shortness of breath or difficulty breathing Mild Absent • Fee
Slide 57: EPIC-SR: Analysis of Time to Symptom Alleviation
EPIC-SR: Analysis of Time to Symptom Alleviation Median (95% confidence interval) Time to Event (Days) PAX PBO p-value EPIC-SR mITT 13.0 13.0 0.335 (N=367) (12-15) (11-15) EPIC-SR mITT1 13.0 13.0 0.469 (N=662) (12-15) (11-14) Abbreviations: PAX = PAXLOVID; PBO = placebo mITT = Modified Intent to Tre
Slide 58: EPIC-SR: Hospitalization and Death through Day 28 mITT1 Population
EPIC-SR: Hospitalization and Death through Day 28 mITT1 Population (≤5 days since symptom onset) EPIC-SR Interim Analysis PAX PBO 3/428 10/426 Hospitalization or death by Day 28 (n/N, %) (0.70) (2.35) RRR 70% p-value 0.051 0/428 0/426 Death by Day 28 (n/N, %) (0.0) (0.0) Abbreviations: PAX = PAXLOVI
Slide 59: EPIC-SR: Approximate 10-fold Reduction in Viral Load at Day 5
EPIC-SR: Approximate 10-fold Reduction in Viral Load at Day 5 EPIC-SR Interim Analysis PAX PBO N 126 128 Least Squares Mean Change from Baseline -3.41 -2.54 Least Squares Mean Difference -0.872 1-sided 80% CI (-∞, -0.70) Dataset: (≤3 days since symptom onset) ~10-fold decrease (1 Log10) in viral loa
Slide 60: EPIC-SR: Interim Analysis – Safety Outcomes
EPIC-SR: Interim Analysis – Safety Outcomes Safety Outcome Results PAX PBO Treatment-emergent adverse events 22% 21% (Most mild in intensity) Serious adverse events 1.4% 1.9% Adverse events leading to 2.1% 1.2% discontinuation of treatment Abbreviations: PAX = PAXLOVID; PBO = placebo Pfizer Announce
Slide 61: Summary of EPIC-HR and EPIC-SR
Summary of EPIC-HR and EPIC-SR • Consistent and robust (~10-fold) viral load reduction in both trials ‒ Strongest viral load reductions reported to date for an oral COVID-19 antiviral • EPIC-HR final results nearly identical to 45% interim analysis results ‒ Efficacy of ≥88% when initiated ≤5 days o
Slide 62: Angela Lukin
Angela Lukin Global President, Hospital Breakthroughs that change patients’ lives
Slide 63: Three Critical Success Factors for Launch
Three Critical Success Factors for Launch Building Confidence Support Broad Drive Urgency to in Protease Inhibitor and Equitable Diagnosis & Treatment Benefit/Risk Profile Access & Coverage 63
Slide 64: Driving Urgency to Diagnosis and Treatment is Critical
Driving Urgency to Diagnosis and Treatment is Critical Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8+ Current: Up to 8 Days before Treatment Initiation Treatment Diagnosis / Initiation (*) and Symptomatic Patients Seeking Treatment Presentation / Testing Results Available Fulfilment (mAbs → +7 day
Slide 65: Building Confidence in the Benefit/Risk Profile
Building Confidence in the Benefit/Risk Profile Largest Comprehensive Overwhelming efficacy Clean genetic toxicology; Development Program for an (final analysis) in high risk Well tolerated clinical profile oral COVID-19 antiviral COVID-19 patients across 3 Patient Populations Showed In Vitro Activi
Slide 66: Commitment to Broad and Equitable Access and Coverage
Commitment to Broad and Equitable Access and Coverage Access Principles Medicines Patent Pool (MPP) Partnership • Tiered pricing approach • Potentially accelerates access to Low- Income and Lower-Middle Income countries • High and Upper Middle-Income countries will pay more than Lower-Income countri
Slide 67: COVID-19 Treatments: Highly Dynamic Given Disease Evolution
COVID-19 Treatments: Highly Dynamic Given Disease Evolution 2022 2023 2024 and Beyond Pandemic Hybrid Endemic Pfizer Expectations • ~155 M in Non MPP markets; • Addressable patient pool Total • ~95 M in MPP markets expected to vary as pandemic Estimated evolves Anticipated durable volumes Addressabl
Slide 68: Frank D'Amelio
Frank D'Amelio Chief Financial Officer and Executive Vice President, Global Supply Breakthroughs that change patients’ lives
Slide 69: 2022 Outlook for Potential COMIRNATY Sales
2022 Outlook for Potential COMIRNATY Sales 4B Expected capacity for doses to be produced in 2022 1.9B Expected doses to be delivered in 2022 based on contracts signed as of mid-November 2021 ~$31B Direct sales and alliance revenues anticipated in 2022 based on contracts signed as of mid-November 202
Slide 70: Q&A
Q&A Breakthroughs that change patients’ lives
Slide 71: Appendix
Appendix Breakthroughs that change patients’ lives
Slide 72: Pfizer-BioNTech Vaccine Supply Chain Project Lightspeed
Pfizer-BioNTech Vaccine Supply Chain Project Lightspeed First phone Started building First clinical First regulatory call to PGS formulation booth batches manufactured authorizations Mar 2020 Jun 2020 Jul 2020 Nov-Dec 2020 Jun 2020 Jul 2020 Sept 2020 Dec 2020 First equipment First freezer farms Firs
Slide 73: Supply Chain Excellence: Accuracy and Speed
Supply Chain Excellence: Accuracy and Speed • We have undertaken the largest capacity expansion in Pfizer’s – and likely the pharmaceutical industry’s – history. • We have reduced our timelines from approximately 110 days from start to vial-ready, and we are now approaching an average of 60 days – a
Slide 74: Details on the Pfizer-BioNTech Vaccine Shipper
Details on the Pfizer-BioNTech Vaccine Shipper • We have specially designed, temperature-controlled shippers utilizing dry ice to maintain recommended temperature conditions up to 30 days of storage. These specialized thermal shippers are roughly the size of a carryon suitcase. • The shippers are pa
Slide 75: Headlines from Vaccine Supply/Release – Distribution Metrics
Headlines from Pfizer-BioNTech Vaccine Supply/Release – Distribution Metrics 2020 – Present Delivery to Final Destination Across 5 Carriers in 1-4 Days > 163 Countries & Territories >44K 98.7% of shipments were delivered within 4 Days Destinations Product Quality Status >600K Boxes 3.22Bn Dosages 99
Slide 76: Freezer Farm Construction
Freezer Farm Construction Pfizer currently has 3,200 deep freezers – increasing to 5,500 by Q2 2022 76
Slide 77: 77
77
Slide 78: Digital, Data and Advanced Analytics Accelerating Pfizer's COVID Efforts
Digital, Data and Advanced Analytics Accelerating Pfizer’s COVID Efforts Supercomputing powers Smart Data Query to Real-time predictive models 75% of site monitoring visits for our research. Accelerated quickly quality-check & of COVID county-level attack vaccine study conducted remotely antiviral r
Slide 79: Hospital Revenue Reconciliation
Hospital Revenue Reconciliation % Operational % Reported Revenues (US$M) Growth Growth 2021 First Nine Months Revenue 6,968 18% 21% Pfizer CentreOne (Included above) 1,348 Meridian (Included above) 203 2021 First Nine Months Revenue, 5,417 7% 10% Excluding Pfizer CentreOne and Meridian* * Pfizer Cen